The drug, Xacduro (sulbactam for injection; durlobactam for injection), works to simultaneously protect itself and kill A. baumannii. In a phase 3 trial, 19 percent of Xacduro patients died, compared to 32 percent of deaths among those who took colistin, a comparator antibiotic.
A. baumannii tops the World Health Organization’s list of critical pathogens that pose a high risk to human health, and the bacteria “can become highly resistant to multiple antibacterial drugs and current treatment options for drug-resistant A. baumannii are limited,” the FDA said.
Xacduro, made by Entasis Therapeutics, is approved for adults.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
